Path to Hepatitis C Elimination: Who Are We Leaving Behind and Why? 🤔

The WHO’s global targets for hepatitis C (HCV) elimination, set in 2016, aim for 80% treatment coverage, 90% reduction in incidence, and 65% reduction in liver-related mortality. However, these targets are at risk, especially for marginalized groups such as people who use drugs (PWUD) and incarcerated individuals. Achieving elimination globally is contingent upon addressing the unique barriers these populations face in accessing care and treatment.

Biomedical Advances in Hepatitis C Treatment 🧬

Direct-acting antiviral therapies, with cure rates above 95%, alongside simplified screening through rapid point-of-care tests, are crucial. However, challenges in resourcing and implementation remain, particularly for vulnerable populations.

Overcoming Barriers to Treatment for Marginalized Groups 🚧

For people who use drugs, barriers like insurance restrictions, criminalization, and stigma continue to impede access to care. However, integrating harm reduction services has shown success in engaging these populations.

Innovative Care Models for Better Access 💡

Innovative care models that integrate treatment with harm reduction services—such as needle exchange programs and methadone therapy—are essential to increase treatment uptake and reduce stigma.

The Role of Prisons in HCV Control 🏛️

Prisons are critical for ongoing transmission. Despite this, many countries fail to integrate services into their prison healthcare systems, hindering global elimination efforts.

Conclusion: Moving Forward in the Fight Against Hepatitis C 🛤️

People who use drugs and incarcerated individuals remain key groups left behind in global elimination strategies. To achieve the 2030 goals, significant policy changes and the integration of these groups into national healthcare systems are required.